INCYTE CORPORATION Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
INCYTE CORPORATION (INCY) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2020-02-13
- INCYTE CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2019-12-31 was $0.00.
- INCYTE CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2019-09-30 was $0.00.
- INCYTE CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2019-06-30 was $0.00.
- INCYTE CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2019-03-31 was $0.00.
- INCYTE CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2019 was $0.00.
- INCYTE CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2018 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $0.00 10-K · filed 2020-02-13 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $0.00 derived: sum of 2 quarters · filed 2019-10-29 | $0.00 10-Q · filed 2019-10-29 | $0.00 derived: sum of 4 quarters · filed 2019-10-29 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-30 | $0.00 10-Q · filed 2019-07-30 | $0.00 derived: sum of 3 quarters · filed 2019-07-30 | $0.00 derived: sum of 4 quarters · filed 2019-07-30 |
| 2019-03-31 | $0.00 10-Q · filed 2019-04-30 | $0.00 derived: sum of 2 quarters · filed 2019-04-30 | $0.00 derived: sum of 3 quarters · filed 2019-04-30 | $0.00 derived: sum of 4 quarters · filed 2019-04-30 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $0.00 derived: sum of 3 quarters · filed 2019-02-14 | $0.00 10-K · filed 2019-02-14 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $0.00 derived: sum of 2 quarters · filed 2018-10-30 | $0.00 10-Q · filed 2018-10-30 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $0.00 10-Q · filed 2018-07-31 | ||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |